Abstract:
Pulmonary emboli (PEs) occur when the pulmonary artery is blocked by foreign material. In one such instance, this foreign material can be a blood clot that may occur from patient risk factors inducing a prothrombotic state. The relationship between COVID-19 vaccines and a prothrombotic state is novel and changing as our understanding of the relationship between the two evolves. The patient in this case study presented with unrelenting and progressive dyspnea, tachycardia, and unilateral lower extremity swelling two days after receiving the second dose of the Pfizer COVID-19 vaccine. After diagnostic testing, the patient was found to have a submassive saddle pulmonary embolism with subsequent right heart strain. This patient was treated with appropriate anticoagulation therapies, including heparin and apixaban, as well as thrombectomy, and made a complete recovery. The possible relationship between COVID-19 vaccines and thrombotic events supports the need for increased awareness of a potential new risk factor behind the development of PE. It is our hope that this case report will help raise awareness of an association despite the lack of incident data at this time.
摘要:
当肺动脉被异物阻塞时,会发生肺栓塞(PE)。在一个这样的例子中,这种异物可能是血凝块,可能是由患者诱发血栓前状态的危险因素引起的。随着我们对两者关系的理解的发展,COVID-19疫苗与血栓形成前状态之间的关系是新的和不断变化的。本病例研究中的患者表现为持续和进行性呼吸困难,心动过速,在接受第二剂辉瑞COVID-19疫苗两天后,单侧下肢肿胀。诊断测试后,该患者被发现患有亚大规模鞍状肺栓塞,随后右心劳损。该患者接受了适当的抗凝治疗,包括肝素和阿哌沙班,以及血栓切除术,完全康复了.COVID-19疫苗与血栓形成事件之间的可能关系支持需要提高对PE发展背后潜在新风险因素的认识。尽管目前缺乏事件数据,但我们希望此病例报告将有助于提高对协会的认识。